# ![@LegendUSMA Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1920583888587706368.png) @LegendUSMA Legend Biotech Medical Affairs

Legend Biotech Medical Affairs posts on X about link, dr, in the, events the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1920583888587706368/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:interactions.svg)

- [--] Week [---] -74%
- [--] Month [-----] +258%
- [--] Months [-----] -8.20%

### Mentions: [--] [#](/creator/twitter::1920583888587706368/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:posts_active.svg)

- [--] Week [--] -30%
- [--] Month [--] +9.10%
- [--] Months [--] +67%

### Followers: [---] [#](/creator/twitter::1920583888587706368/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:followers.svg)

- [--] Week [---] +0.87%
- [--] Month [---] +3.60%
- [--] Months [---] +100%

### CreatorRank: undefined [#](/creator/twitter::1920583888587706368/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1920583888587706368/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [technology brands](/list/technology-brands) 

**Social topic influence**
[link](/topic/link), [dr](/topic/dr), [in the](/topic/in-the), [events](/topic/events), [study](/topic/study), [improved](/topic/improved), [longterm](/topic/longterm), [science](/topic/science), [cart](/topic/cart), [salt](/topic/salt)

**Top accounts mentioned or mentioned by**
[@surbhisidanamd](/creator/undefined) [@bhemato](/creator/undefined) [@comycongress](/creator/undefined) [@yilinmdphd](/creator/undefined) [@moffittnews](/creator/undefined) [@endmyeloma](/creator/undefined) [@plasmacellpete](/creator/undefined) [@strousechris](/creator/undefined) [@leshune](/creator/undefined) [@amokhanmd](/creator/undefined) [@sandsjacob](/creator/undefined) [@tombmt133](/creator/undefined) [@cohenadmmdoc](/creator/undefined) [@noopurrajemd](/creator/undefined) [@abhinavdeol](/creator/undefined) [@berdejajesus](/creator/undefined) [@lesokhinmd](/creator/undefined) [@dradrianarossi](/creator/undefined) [@szusmani](/creator/undefined) [@adamjschoenfeld](/creator/undefined)

**Top assets mentioned**
[Frontline Ltd. (FRO)](/topic/$fro)
### Top Social Posts
Top posts by engagements in the last [--] hours

"See our Community Guidelines"  
[X Link](https://x.com/LegendUSMA/status/1921955792921428019)  2025-05-12T15:49Z [--] followers, [---] engagements


"Welcome to @LegendUSMA We are dedicated to sharing updates on the research and clinical development of innovative cellular therapies to improve the lives of patients. We hope you will follow us and look forward to the scientific exchange. See our community guidelines. #CellRx"  
[X Link](https://x.com/LegendUSMA/status/1922690874179453082)  2025-05-14T16:30Z [--] followers, [---] engagements


"For US HCPs see an e-poster at @COMyCongress on MRD negativity outcomes in the Phase [--] CARTITUDE-4 trial of a BCMA-directed CAR-T cell therapy vs standard of care in patients with Len-refractory multiple myeloma after 1-3 prior lines of therapy: #mmsm https://bit.ly/4kgHqQD https://bit.ly/4kgHqQD"  
[X Link](https://x.com/LegendUSMA/status/1923391260586311711)  2025-05-16T14:53Z [--] followers, [---] engagements


"For US HCPs see an e-poster at @COMyCongress of infections and immune reconstitution in the Phase [--] CARTITUDE-4 trial of a BCMA-directed CAR-T cell therapy vs standard of care in patients with Len-refractory multiple myeloma after 1-3 prior lines: #mmsm https://bit.ly/4dBqh2h https://bit.ly/4dBqh2h"  
[X Link](https://x.com/LegendUSMA/status/1923435550914097506)  2025-05-16T17:49Z [--] followers, [---] engagements


"For US HCPs see a @COMyCongress presentation showing effectiveness of bridging therapy corresponds to improved outcomes after BCMA-directed CAR-T therapy in the Phase [--] CARTITUDE-4 trial of patients with relapsed Len-refractory multiple myeloma: #mmsm https://bit.ly/4keA4Nv https://bit.ly/4keA4Nv"  
[X Link](https://x.com/LegendUSMA/status/1923845985945460836)  2025-05-17T21:00Z [--] followers, [---] engagements


"For US HCPs see a @COMyCongress encore presentation of overall survival outcomes with a BCMA-directed CAR-T therapy vs standard of care in the Phase [--] CARTITUDE-4 trial for relapsed Len-refractory multiple myeloma: #mmsm https://bit.ly/4keA4Nv https://bit.ly/4keA4Nv"  
[X Link](https://x.com/LegendUSMA/status/1923891281438310598)  2025-05-18T00:00Z [--] followers, [---] engagements


"Now published for US HCPs: results of a matching-adjusted indirect comparison of a BCMA-directed CAR-T cell therapy vs standard of care therapies for patients with relapsed/refractory multiple myeloma. Read more: #mmsm @SurbhiSidanaMD @leshune @AMoKhanMD https://bit.ly/4jY248w https://bit.ly/4jY248w"  
[X Link](https://x.com/LegendUSMA/status/1924489165166571555)  2025-05-19T15:35Z [--] followers, [---] engagements


"We are excited to be in Chicago for #ASCO25 Come by our Medical Booth (#11113) to meet our medical team and learn more about the research were presenting at this years meeting. See the ASCO hub for our abstracts. #mmsm #lcsm #GastricCancer #Pancsm #CellRx"  
[X Link](https://x.com/LegendUSMA/status/1928090806092485102)  2025-05-29T14:07Z [--] followers, [---] engagements


"For US HCPs at #ASCO25 Dr. David Zhen presents preliminary results of a Phase [--] study of an autologous Claudin 18.2-targeted CAR-T therapy in patients with advanced gastroesophageal adenocarcinoma. For more: #GastricCancer #EsophagealCancer #Pancsm http://bit.ly/43d8DOx http://bit.ly/43d8DOx"  
[X Link](https://x.com/LegendUSMA/status/1928520086001758660)  2025-05-30T18:33Z [--] followers, [---] engagements


"For US HCPs at #ASCO25 Dr. Jacob Sands (@sands_jacob) presents results of a Phase [--] study of an armored DLL3-targeted CAR-T therapy in patients with relapsed small cell lung cancer and large cell neuroendocrine carcinoma. For more: #sclc #lcnec #lcsm https://bit.ly/4d06n0e https://bit.ly/4d06n0e"  
[X Link](https://x.com/LegendUSMA/status/1928775514887495966)  2025-05-31T11:28Z [--] followers, [---] engagements


"For US HCPs at #ASCO25 Dr. Surbhi Sidana (@SurbhiSidanaMD) presents survival outcomes of subgroups in the CARTITUDE-4 study after treatment with a BCMA-directed CAR-T cell product for early line relapsed/refractory multiple myeloma. For more: #mmsm http://bit.ly/4d3YYwX http://bit.ly/4d3YYwX"  
[X Link](https://x.com/LegendUSMA/status/1929155478015152499)  2025-06-01T12:38Z [--] followers, [----] engagements


"For US HCPs at #ASCO25 Dr. Peter Voorhees (@PlasmaCellPete) presents long-term follow-up of the CARTITUDE-1 study with [--] years of follow-up after treatment with a BCMA-directed CAR-T cell product for relapsed/refractory multiple myeloma. For more: #mmsm http://bit.ly/3GVbyTd http://bit.ly/3GVbyTd"  
[X Link](https://x.com/LegendUSMA/status/1929883702277914681)  2025-06-03T12:51Z [--] followers, [---] engagements


"NOW PUBLISHED for US HCPs: Long-term remission and survival after treatment with a BCMA-directed CAR-T cell therapy in CARTITUDE-1 for patients with relapsed/refractory multiple myeloma. Read more: #mmsm https://bit.ly/4dG13zu https://bit.ly/4dG13zu"  
[X Link](https://x.com/LegendUSMA/status/1929887991968772538)  2025-06-03T13:08Z [--] followers, [---] engagements


"Authors: Sundar Jagannath @TomBmt133 @YiLinMDPhD @CohenAd_MMdoc @NoopurRajeMD Myo Htut @abhinav_deol Mounzer Agha @BerdejaJesus @LesokhinMd Jessica Liegel @Dr_AdrianaRossi Alex Lieberman-Cribbin @szusmani @bhemato Samir Parekh Andrzej Jakubowiak @PlasmaCellPete"  
[X Link](https://x.com/LegendUSMA/status/1929887993570988387)  2025-06-03T13:08Z [--] followers, [----] engagements


"For US HCPs at #EHA25 see Dr. Sundar Jagannath (Mount Sinai) present long-term follow-up of the CARTITUDE-1 study with [--] years of follow-up after treatment with a BCMA-directed CAR-T cell product for relapsed/refractory multiple myeloma. #mmsm https://bit.ly/4jvExLi https://bit.ly/4jvExLi"  
[X Link](https://x.com/LegendUSMA/status/1933176032384999491)  2025-06-12T14:54Z [--] followers, [---] engagements


"For US HCPs at #EHA25 see Dr. Yi Lin (@YiLinMDPhD) present an analysis of absolute lymphocyte count (ALC) as a key biomarker for monitoring safety after a BCMA-directed CAR-T cell therapy: #mmsm https://bit.ly/3Fodofe https://bit.ly/3Fodofe"  
[X Link](https://x.com/LegendUSMA/status/1933872058737602625)  2025-06-14T13:00Z [--] followers, [---] engagements


"For US HCPs at #EHA25 Dr. Yael Cohen presents survival outcomes of subgroups in the CARTITUDE-4 study after treatment with a BCMA-directed CAR-T cell product for early line relapsed/refractory multiple myeloma. For more: #mmsm http://bit.ly/4kdkMcx http://bit.ly/4kdkMcx"  
[X Link](https://x.com/LegendUSMA/status/1933902252282114425)  2025-06-14T15:00Z [--] followers, [---] engagements


"News from the US Food and Drug Administration (FDA): The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated. A thread 🧵"  
[X Link](https://x.com/LegendUSMA/status/1939761084346327538)  2025-06-30T19:00Z [--] followers, [--] engagements


"For US HCPs at #SOHO2025 Yi Lin (@YiLinMDPhD) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. #mmsm"  
[X Link](https://x.com/LegendUSMA/status/1963232511879676212)  2025-09-03T13:28Z [--] followers, [---] engagements


"For US #HCPs at #SOHO2025 Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents an encore presentation analyzing survival outcomes of various subgroups in CARTITUDE-4 of a BCMA-directed #CART therapy versus standard of care. #mmsm"  
[X Link](https://x.com/LegendUSMA/status/1963283219408990390)  2025-09-03T16:49Z [--] followers, [---] engagements


"For US HCPs at #WCLC25 see Dr. Adam J. Schoenfeld (@AdamJSchoenfeld) present results from a phase [--] study of a DLL3-targeted #CART cell therapy in small cell lung and large cell neuroendocrine cancers. See more: #lcsm #sclc #lcnec http://bit.ly/4g2po3W http://bit.ly/4g2po3W"  
[X Link](https://x.com/LegendUSMA/status/1965354499653976574)  2025-09-09T10:00Z [--] followers, [--] engagements


"For US HCPs at #IMS25 Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/4pfEirI https://bit.ly/4pfEirI"  
[X Link](https://x.com/LegendUSMA/status/1968310394101113107)  2025-09-17T13:45Z [--] followers, [---] engagements


"For US HCPs at #IMS25 see Dr. Yael Cohen present updated results from CARTITUDE-2 Cohort D of a BCMA-directed #CART therapy +/- lenalidomide maintenance for multiple myeloma patients with a suboptimal response to frontline ASCT. Abstracts here: #mmsm https://bit.ly/3VG16Dg https://bit.ly/3VG16Dg"  
[X Link](https://x.com/LegendUSMA/status/1969086407911084245)  2025-09-19T17:09Z [--] followers, [--] engagements


"For US HCPs at #IMS25 Yi Lin (@YiLinMDPhD) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. For IMS abstracts link here: #mmsm http://bit.ly/45VN5Yf http://bit.ly/45VN5Yf"  
[X Link](https://x.com/LegendUSMA/status/1968298859932848248)  2025-09-17T12:59Z [---] followers, [---] engagements


"For US HCPs at #IMS25 Dr. Murali Janakiram (@JanakiramMurali) from City of Hope presents a descriptive analysis of healthcare resource utilization following inpatient or outpatient infusion of a BCMA-directed #CART therapy. Abstracts here: #mmsm https://bit.ly/3IaTAx8 https://bit.ly/3IaTAx8"  
[X Link](https://x.com/LegendUSMA/status/1969025697726320662)  2025-09-19T13:08Z [--] followers, [---] engagements


"Join Dr. Luciano Costa (@End_myeloma) for an oral presentation at #ASH25 to learn about the long-term progression-free survival benefit with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma. For more link here: #mmsm https://bit.ly/3LOC6bn https://bit.ly/3LOC6bn"  
[X Link](https://x.com/LegendUSMA/status/1997301139071771079)  2025-12-06T13:44Z [---] followers, [----] engagements


"Dr. Jingwei Yu (Tianjin Medical University Cancer Institute) presents a phase [--] study of a novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell NHL. Link: #lymsm #CART https://bit.ly/4ocJE5j https://bit.ly/4ocJE5j"  
[X Link](https://x.com/LegendUSMA/status/1997328849323897209)  2025-12-06T15:34Z [---] followers, [---] engagements


"Dr. Binod Dhakal (@bhemato) presents at #ASH25 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase [--] CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART https://bit.ly/4oRFzo9 https://bit.ly/4oRFzo9"  
[X Link](https://x.com/LegendUSMA/status/1997370555536683319)  2025-12-06T18:20Z [---] followers, [---] engagements


"Robert Bowden (Johnson & Johnson) presents at #ASH25 on improved manufacturing outcomes with BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm https://bit.ly/3KeuC0Q https://bit.ly/3KeuC0Q"  
[X Link](https://x.com/LegendUSMA/status/1997380930286072158)  2025-12-06T19:01Z [---] followers, [---] engagements


"Dr. Doris Hansen presents at #ASH25 on bridging therapy response and low pre-lymphodepletion plasma cell burden associations with improved safety and efficacy outcomes of a BCMA-directed #CART therapy in multiple myeloma. Link: #mmsm. https://bit.ly/4p32Rr6 https://bit.ly/4p32Rr6"  
[X Link](https://x.com/anyuser/status/1997401890812793050)  2025-12-06T20:24Z [---] followers, [---] engagements


"At #ASH25 Dr. Doris Hansen presents real-world incidence and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm. https://bit.ly/3KfHNi7 https://bit.ly/3KfHNi7"  
[X Link](https://x.com/anyuser/status/1997696306278797566)  2025-12-07T15:54Z [---] followers, [---] engagements


"Dr. Christopher Strouse (@strouse_chris) presents comparative efficacy of a BCMA-directed #CART cell therapy vs a BCMA-directed ADC-based triplet in patients with relapsed/refractory multiple myeloma after [--] prior therapies using an MAIC. Link: #mmsm. https://bit.ly/48qdYVh https://bit.ly/48qdYVh"  
[X Link](https://x.com/anyuser/status/1997715168793612589)  2025-12-07T17:09Z [---] followers, [---] engagements


"Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/48fwXRi https://bit.ly/48fwXRi"  
[X Link](https://x.com/anyuser/status/1998021147917791403)  2025-12-08T13:25Z [---] followers, [---] engagements


"A heartfelt thank you to all who joined us at #ASH25 attended sessions and visited our posters. Together were pushing boundaries in #CART therapy and accelerating better outcomes for patients with #mmsm and #lymsm"  
[X Link](https://x.com/anyuser/status/1998498870704361546)  2025-12-09T21:03Z [---] followers, [---] engagements


"ICYMI: we recently celebrated the opening of our new [-----] square foot state-of-the-art cell therapy research facility in downtown Philadelphia that will help support Legends pipeline of next-generation cell therapies. For more about Legends pipeline: https://bit.ly/3XJDsqu https://bit.ly/3XJDsqu"  
[X Link](https://x.com/anyuser/status/2001319749435654649)  2025-12-17T15:53Z [---] followers, [---] engagements


"NEW in Lancet Oncology: Latest findings from CARTITUDE-4 study report on survival outcomes in patients with relapsed/refractory multiple myeloma treated with a BCMA #CART therapy as early as first relapse compared with standard of care. #mmsm Read more: https://bit.ly/4qJUkKp https://bit.ly/4qJUkKp"  
[X Link](https://x.com/anyuser/status/2009320058313662946)  2026-01-08T17:43Z [---] followers, [---] engagements


"US-based authors: Dr. Binod Dhakal (@bhemato) of MCW and Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford"  
[X Link](https://x.com/anyuser/status/2009320060746358835)  2026-01-08T17:43Z [---] followers, [---] engagements


"Dr. Binod Dhakal (@bhemato) presents at #TANDEM26 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase [--] CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART https://bit.ly/4pSeNMc https://bit.ly/4pSeNMc"  
[X Link](https://x.com/anyuser/status/2019460005955600433)  2026-02-05T17:15Z [---] followers, [---] engagements


"Dr. Surbhi Sidana (@SurbhiSidanaMD) presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in len-refractory multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/49AV3HZ https://bit.ly/49AV3HZ"  
[X Link](https://x.com/anyuser/status/2019515518370103727)  2026-02-05T20:56Z [---] followers, [---] engagements


"At #TANDEM26 Dr. Doris Hansen of @MoffittNews presents characterization and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm. https://bit.ly/4qH1I9G https://bit.ly/4qH1I9G"  
[X Link](https://x.com/anyuser/status/2019520971405947024)  2026-02-05T21:18Z [---] followers, [---] engagements


"Robert Bowden (Johnson & Johnson) presents at #TANDEM26 on improved manufacturing outcomes with out-of-specification BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm https://bit.ly/3NxfNI9 https://bit.ly/3NxfNI9"  
[X Link](https://x.com/anyuser/status/2019568185876656479)  2026-02-06T00:25Z [---] followers, [---] engagements


"At the [----] ASH Annual Meeting our focus remains clear: driving innovation that puts patients at the center. Excited to collaborate and share progress with the hematology community For more link here: #mmsm #lymsm https://bit.ly/4ps38UB https://bit.ly/4ps38UB"  
[X Link](https://x.com/LegendUSMA/status/1996600574091886783)  2025-12-04T15:20Z [---] followers, [---] engagements


"Excited for the #TANDEM26 Annual Meeting and the chance to advance patient-centered innovation together. We hope you will connect with our Medical Affairs team at Booth #301 for those attending live in Salt Lake City. For more on our science: #mmsm #CART https://bit.ly/4sZ9Wvy https://bit.ly/4sZ9Wvy"  
[X Link](https://x.com/anyuser/status/2018775638073581921)  2026-02-03T19:56Z [---] followers, [---] engagements


"See Dr. Luciano Costa (@End_myeloma) at #TANDEM26 present long-term progression-free survival outcomes with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma in the CARTITUDE-4 study. For more link here: #mmsm https://bit.ly/3LY4fx6 https://bit.ly/3LY4fx6"  
[X Link](https://x.com/anyuser/status/2019433626413178926)  2026-02-05T15:31Z [---] followers, [---] engagements


"Dr. Doris Hansen from @MoffittNews presents at #TANDEM26 on bridging therapy response and pre-lymphodepletion plasma cell burden as determinants of BCMA-directed safety and efficacy outcomes in relapsed/refractory multiple myeloma. Link: #mmsm. https://bit.ly/3LOuExk https://bit.ly/3LOuExk"  
[X Link](https://x.com/anyuser/status/2019504548411568583)  2026-02-05T20:12Z [---] followers, [---] engagements


"Thank you to those who joined us during #Tandem26 and engaged with our data. Your continued partnership advances the science of cellular therapy and supports progress in care for patients with multiple myeloma. Looking forward to continuing the momentum at #ASCO26. #mmsm #CART"  
[X Link](https://x.com/anyuser/status/2020183229949706660)  2026-02-07T17:09Z [---] followers, [---] engagements


"Our VP & Head of Early-Stage Drug Dev Dong Geng will participate in a panel on in vivo cell therapy Feb. [--] @ 1:20 p.m. at #IO360Summit. 📍 Track 2: Cell Therapy Plenary 🎤 In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment https://io360summit.com/ https://io360summit.com/"  
[X Link](https://x.com/anyuser/status/2020869819197739063)  2026-02-09T14:38Z [----] followers, [---] engagements


"Thank you to those who joined us during #Tandem26 and engaged with our data. Your continued partnership advances the science of cellular therapy and supports progress in care for patients with multiple myeloma. Looking forward to continuing the momentum at #ASCO26. #mmsm #CART"  
[X Link](https://x.com/anyuser/status/2020183229949706660)  2026-02-07T17:09Z [---] followers, [---] engagements


"Robert Bowden (Johnson & Johnson) presents at #TANDEM26 on improved manufacturing outcomes with out-of-specification BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm https://bit.ly/3NxfNI9 https://bit.ly/3NxfNI9"  
[X Link](https://x.com/anyuser/status/2019568185876656479)  2026-02-06T00:25Z [---] followers, [---] engagements


"At #TANDEM26 Dr. Doris Hansen of @MoffittNews presents characterization and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm. https://bit.ly/4qH1I9G https://bit.ly/4qH1I9G"  
[X Link](https://x.com/anyuser/status/2019520971405947024)  2026-02-05T21:18Z [---] followers, [---] engagements


"Dr. Surbhi Sidana (@SurbhiSidanaMD) presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in len-refractory multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/49AV3HZ https://bit.ly/49AV3HZ"  
[X Link](https://x.com/anyuser/status/2019515518370103727)  2026-02-05T20:56Z [---] followers, [---] engagements


"Dr. Doris Hansen from @MoffittNews presents at #TANDEM26 on bridging therapy response and pre-lymphodepletion plasma cell burden as determinants of BCMA-directed safety and efficacy outcomes in relapsed/refractory multiple myeloma. Link: #mmsm. https://bit.ly/3LOuExk https://bit.ly/3LOuExk"  
[X Link](https://x.com/anyuser/status/2019504548411568583)  2026-02-05T20:12Z [---] followers, [---] engagements


"Dr. Binod Dhakal (@bhemato) presents at #TANDEM26 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase [--] CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART https://bit.ly/4pSeNMc https://bit.ly/4pSeNMc"  
[X Link](https://x.com/anyuser/status/2019460005955600433)  2026-02-05T17:15Z [---] followers, [---] engagements


"See Dr. Luciano Costa (@End_myeloma) at #TANDEM26 present long-term progression-free survival outcomes with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma in the CARTITUDE-4 study. For more link here: #mmsm https://bit.ly/3LY4fx6 https://bit.ly/3LY4fx6"  
[X Link](https://x.com/anyuser/status/2019433626413178926)  2026-02-05T15:31Z [---] followers, [---] engagements


"Excited for the #TANDEM26 Annual Meeting and the chance to advance patient-centered innovation together. We hope you will connect with our Medical Affairs team at Booth #301 for those attending live in Salt Lake City. For more on our science: #mmsm #CART https://bit.ly/4sZ9Wvy https://bit.ly/4sZ9Wvy"  
[X Link](https://x.com/anyuser/status/2018775638073581921)  2026-02-03T19:56Z [---] followers, [---] engagements


"We will present data on our #CART #CellTherapy for #MultipleMyeloma at #Tandem26 Meetings of @ASTCT and @CIBMTR in Salt Lake City. Six posters will highlight efficacy safety and real-world outcomes supporting earlier use in the treatment journey. https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-present-carvyktir-data-2026-tandem-meetings https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-present-carvyktir-data-2026-tandem-meetings"  
[X Link](https://x.com/anyuser/status/2013963149079105818)  2026-01-21T13:13Z [----] followers, [---] engagements


"An updated CARTITUDE-4 analysis published in @TheLancetOncol reports outcomes evaluating earlier use of our #CART #CellTherapy for #MultipleMyeloma adding to the growing clinical evidence informing treatment decisions and future research. 🔗 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00653-9/fulltext https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00653-9/fulltext"  
[X Link](https://x.com/anyuser/status/2011438153320525994)  2026-01-14T14:00Z [----] followers, [---] engagements


"NEW in Lancet Oncology: Latest findings from CARTITUDE-4 study report on survival outcomes in patients with relapsed/refractory multiple myeloma treated with a BCMA #CART therapy as early as first relapse compared with standard of care. #mmsm Read more: https://bit.ly/4qJUkKp https://bit.ly/4qJUkKp"  
[X Link](https://x.com/anyuser/status/2009320058313662946)  2026-01-08T17:43Z [---] followers, [---] engagements


"US-based authors: Dr. Binod Dhakal (@bhemato) of MCW and Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford"  
[X Link](https://x.com/anyuser/status/2009320060746358835)  2026-01-08T17:43Z [---] followers, [---] engagements


"ICYMI: we recently celebrated the opening of our new [-----] square foot state-of-the-art cell therapy research facility in downtown Philadelphia that will help support Legends pipeline of next-generation cell therapies. For more about Legends pipeline: https://bit.ly/3XJDsqu https://bit.ly/3XJDsqu"  
[X Link](https://x.com/anyuser/status/2001319749435654649)  2025-12-17T15:53Z [---] followers, [---] engagements


"A heartfelt thank you to all who joined us at #ASH25 attended sessions and visited our posters. Together were pushing boundaries in #CART therapy and accelerating better outcomes for patients with #mmsm and #lymsm"  
[X Link](https://x.com/anyuser/status/1998498870704361546)  2025-12-09T21:03Z [---] followers, [---] engagements


"Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/48fwXRi https://bit.ly/48fwXRi"  
[X Link](https://x.com/anyuser/status/1998021147917791403)  2025-12-08T13:25Z [---] followers, [---] engagements


"Dr. Christopher Strouse (@strouse_chris) presents comparative efficacy of a BCMA-directed #CART cell therapy vs a BCMA-directed ADC-based triplet in patients with relapsed/refractory multiple myeloma after [--] prior therapies using an MAIC. Link: #mmsm. https://bit.ly/48qdYVh https://bit.ly/48qdYVh"  
[X Link](https://x.com/anyuser/status/1997715168793612589)  2025-12-07T17:09Z [---] followers, [---] engagements


"At #ASH25 Dr. Doris Hansen presents real-world incidence and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm. https://bit.ly/3KfHNi7 https://bit.ly/3KfHNi7"  
[X Link](https://x.com/anyuser/status/1997696306278797566)  2025-12-07T15:54Z [---] followers, [---] engagements


"Dr. Doris Hansen presents at #ASH25 on bridging therapy response and low pre-lymphodepletion plasma cell burden associations with improved safety and efficacy outcomes of a BCMA-directed #CART therapy in multiple myeloma. Link: #mmsm. https://bit.ly/4p32Rr6 https://bit.ly/4p32Rr6"  
[X Link](https://x.com/anyuser/status/1997401890812793050)  2025-12-06T20:24Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing